Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Clinical trial NCT04379518 · TERMINATED

Trial details

NCT number: NCT04379518
Sponsor: Roswell Park Cancer Institute
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Symptomatic COVID-19 Infection Laboratory-Confirmed

Start date: 2020-11-17
Primary completion: 2023-03-15
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.